Comparison of the effect of Erythropoietin, L-Carnitine and Erythropoietin plus L-Carnitine in correction of anemia in chronic haemodialysis patients

ISRCTN ISRCTN96315193
DOI https://doi.org/10.1186/ISRCTN96315193
Secondary identifying numbers N/A
Submission date
07/08/2005
Registration date
11/08/2005
Last edited
25/09/2009
Recruitment status
No longer recruiting
Overall study status
Completed
Condition category
Urological and Genital Diseases
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data
Record updated in last year

Plain English summary of protocol

Not provided at time of registration

Contact information

Dr Hamid Tayebi Khosroshahi
Scientific

Dialysis Center
Imam Hospital
Daneshgah Street
Tabriz
Iran

Phone +98 411 3344339
Email drtayebikh@yahoo.com

Study information

Study designRandomised controlled trial
Primary study designInterventional
Secondary study designRandomised controlled trial
Study setting(s)Not specified
Study typeTreatment
Scientific title
Study acronymCarnitine-Epo
Study objectivesAnemia in chronic haemodialysis patients is improved by administration of Erythropoietin or L-Carnitine or Erythropoietin plus L-Carnitine.
Ethics approval(s)Not provided at time of registration
Health condition(s) or problem(s) studiedChronic Renal Failure (End-Stage Renal Disease [ESRD])
Intervention1. Administration of rHu-EPO 4000 IU/week, subcutaneously (SC) (2000 IU, twice weekly) for 3 months (N = 20)
2. Administration of L-Carnitine 500 mg/day, orally, for 3 months (N = 15)
3. Administration of rHu-EPO 4000 IU/week, SC PLUS L-Carnitine 500 mg/day, orally, for 3 months (N = 15)
Intervention typeDrug
Pharmaceutical study type(s)
PhaseNot Specified
Drug / device / biological / vaccine name(s)Erythropoietin, L-Carnitine
Primary outcome measureHaemoglobin level
Secondary outcome measuresNot provided at time of registration
Overall study start date01/03/2003
Completion date01/03/2005

Eligibility

Participant type(s)Patient
Age groupAdult
SexBoth
Target number of participants50
Key inclusion criteria1. Dialysis for more than 6 months
2. Hb less than 11 g/dl
Key exclusion criteria1. Active infectious disease
2. Active bleeding disorders
Date of first enrolment01/03/2003
Date of final enrolment01/03/2005

Locations

Countries of recruitment

  • Iran

Study participating centre

Dialysis Center
Tabriz
Iran

Sponsor information

Tabriz University of Medical Sciences (Iran)
University/education

Daneshgah Street
Tabriz
Iran

Website http://www.tbzmed.ac.ir
ROR logo "ROR" https://ror.org/04krpx645

Funders

Funder type

University/education

Tabriz University of Medical Sciences (Iran)

No information available

Results and Publications

Intention to publish date
Individual participant data (IPD) Intention to shareNo
IPD sharing plan summaryNot provided at time of registration
Publication and dissemination planNot provided at time of registration
IPD sharing plan